ASTRAZENECA WKN: 886455 ISIN: GB0009895292 Forum: Aktien Thema: Hauptdiskussion

8 July 2021 AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.

Tezepelumab regulatory submission accepted and granted FDA Priority Review in the US for the treatment of patients with asthma

https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-alexion-transaction-cleared-in-the-eu.html

6 July 2021 AstraZeneca's proposed acquisition of Alexion Pharmaceuticals, Inc. (Alexion) has achieved an important step towards completion by having cleared the European Commission review.

Sie hebt schon gut ab. Seit Anfang März von 78 bis jetzt auf 100 ist doch ganz normal

Ich hoffe das die jetzt langsam anhebt

Das sind gute Nachrichten

Nirsevimab MEDLEY Phase II/III trial demonstrated favourable safety and tolerability profile in infants at high risk of RSV 28 June 2021 The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season.

Forxiga recommended for approval in the EU by CHMP for the treatment of patients with chronic kidney disease 28 June 2021 AstraZeneca’s Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).

AstraZeneca Appoints Dr. Susan Galbraith as Executive Vice President, Oncology Research & Development 28 June 2021 AstraZeneca today appointed Dr. Susan Galbraith to lead Oncology Research & Development from initial discovery through late-stage development. Her appointment follows the passing of José Baselga earlier this year. She will join the Company’s Senior Executive Team and report to Chief Executive Officer, Pascal Soriot.

Vaxzevria induced immunity for at least one year following a single dose and strong immune responses following either a late second dose or a third dose 28 June 2021 A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose.

Es gaben so viele gute news heut! 👏

Das wehre schön

Die soll entiich auf 180 steigen. Langsam oder schnell mir egal 😎

Hoffentlich 🍻

Heute fällt die 100